canceldeath
Registry update — unassessed

A Double-Blind, Randomised, Placebo-Controlled Study Evaluating the Effects of a Novel Multi-Targeted Dermatologist-Formulated Oral Supplement on Skin, Hair, Sleep, Energy, Cognition, Libido, and Longevity

Trial registry update: ACTIVE_NOT_RECRUITING. No results reported in the supplied registry record.

RCTMinor significance
Reporter brief

What this changes

The finding has not established an approved change to our evidence assessment.

Source date: Sep 18, 2026 · Discovered: Sep 19, 2026 · Assessed: — · Research update

What it does not prove

  • The abstract provides no numerical results, effect sizes, or p-values, making it impossible to assess whether observed differences were meaningful or statistically significant. The supplement contains multiple active ingredients beyond omega-3s alone, so any effects cannot be attributed to omega-3 fatty acids specifically. A 12-week timeframe cannot establish whether any short-term changes persist or predict longer-term health outcomes like longevity, despite the study's title.

Extracted from supplied source material; model confidence is not a measured probability of correctness.

Design
Rct
Sample size
—
Duration
3 months
Population
Healthy adults aged 35 to 65 years
Primary outcome
Skin condition (assessed by instrumental measurements, trained-assessor visual grading, and participant questionnaires)
Effect size
—
Significance
Not reported
Journal
IDI Skincare Limited
Published
Sep 18, 2026

Funding: Sponsored by IDI Skincare Limited; conducted by Eurofins Product Testing Services Ltd (trading as Eurofins Alba) in Edinburgh, United Kingdom

Conflicts: Study sponsored by the manufacturer of the intervention product (IDI Skincare Limited), which is a substantial conflict of interest

Recorded source passages

Abstract or registry material supplied for assessment; source version 1. This is not a claim of full-text review.

This study evaluated the effects of a daily oral supplement regimen (Advanced ID Brain, Heart and Eye Omega Gel Capsules taken with Advanced ID Longevity and Collagen Complex Powder) on measures of skin condition, hair, sleep, energy, cognition and sexual wellbeing in healthy adults aged 35 to 65 years.
Participants were randomised in a 2:1 ratio to receive either the active supplement regimen or a matched placebo regimen once daily with food for 12 weeks.
Instrumental skin measurements, trained-assessor visual grading and participant questionnaires were performed at baseline (Day 0), Day 28 and Day 84. Hair imaging and cognitive testing were performed at baseline and Day 84.
The study was single-centre, sponsored by IDI Skincare Limited and conducted by Eurofins Product Testing Services Ltd (trading as Eurofins Alba) in Edinburgh, United Kingdom.

Source versions

Version 1: Superseded

Version 1: Unassessed

Assessment history

One thread per scientific event, no matter how many outlets covered it.

Sign in to join the discussion.

No comments yet

Be the first to weigh in on this evidence.